Single User License
INR 136040
Site License
INR 272080
Corporate User License
INR 408120

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Metastatic Adenocarcinoma of The Pancreas-Pipeline Review, H2 2016

Metastatic Adenocarcinoma of The Pancreas-Pipeline Review, H2 2016


  Request for Sample Report

Executive Summary

Metastatic Adenocarcinoma of The Pancreas-Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Metastatic Adenocarcinoma of The Pancreas-Pipeline Review, H2 2016', provides an overview of the Metastatic Adenocarcinoma of The Pancreas pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Metastatic Adenocarcinoma of The Pancreas, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Metastatic Adenocarcinoma of The Pancreas and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Metastatic Adenocarcinoma of The Pancreas

The report reviews pipeline therapeutics for Metastatic Adenocarcinoma of The Pancreas by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Metastatic Adenocarcinoma of The Pancreas therapeutics and enlists all their major and minor projects

The report assesses Metastatic Adenocarcinoma of The Pancreas therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Metastatic Adenocarcinoma of The Pancreas

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Metastatic Adenocarcinoma of The Pancreas

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Metastatic Adenocarcinoma of The Pancreas pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Metastatic Adenocarcinoma of The Pancreas Overview 10

Therapeutics Development 11

Pipeline Products for Metastatic Adenocarcinoma of The Pancreas-Overview 11

Pipeline Products for Metastatic Adenocarcinoma of The Pancreas-Comparative Analysis 12

Metastatic Adenocarcinoma of The Pancreas-Therapeutics under Development by Companies 13

Metastatic Adenocarcinoma of The Pancreas-Therapeutics under Investigation by Universities/Institutes 15

Metastatic Adenocarcinoma of The Pancreas-Pipeline Products Glance 16

Late Stage Products 16

Clinical Stage Products 17

Early Stage Products 18

Metastatic Adenocarcinoma of The Pancreas-Products under Development by Companies 19

Metastatic Adenocarcinoma of The Pancreas-Products under Investigation by Universities/Institutes 21

Metastatic Adenocarcinoma of The Pancreas-Companies Involved in Therapeutics Development 22

AbbVie Inc 22

Aduro BioTech, Inc. 23

Array BioPharma Inc. 24

Axcentua Pharmaceuticals AB 25

Berg LLC 26

Boehringer Ingelheim GmbH 27

Boston Biomedical, Inc. 28

CTI BioPharma Corp. 29

CytRx Corporation 30

Daiichi Sankyo Company, Limited 31

Eleison Pharmaceuticals LLC 32

Gilead Sciences, Inc. 33

GlaxoSmithKline Plc 34

Incyte Corporation 35

MabVax Therapeutics Holdings, Inc. 36

Merrimack Pharmaceuticals, Inc. 37

NewLink Genetics Corporation 38

Novartis AG 39

Oncolytics Biotech Inc. 40

Pfizer Inc. 41

Phoenix Biotechnology, Inc. 42

Targovax ASA 43

Metastatic Adenocarcinoma of The Pancreas-Therapeutics Assessment 44

Assessment by Monotherapy Products 44

Assessment by Combination Products 45

Assessment by Target 46

Assessment by Mechanism of Action 49

Assessment by Route of Administration 52

Assessment by Molecule Type 54

Drug Profiles 56

(curcumin + gemcitabine hydrochloride + paclitaxel)-Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

aldoxorubicin hydrochloride-Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

AXP-10711-Drug Profile 71

Product Description 71

Mechanism Of Action 71

R&D Progress 71

BI-853520-Drug Profile 73

Product Description 73

Mechanism Of Action 73

R&D Progress 73

binimetinib-Drug Profile 74

Product Description 74

Mechanism Of Action 74

R&D Progress 74

Cellular Immunotherapy for Oncology-Drug Profile 81

Product Description 81

Mechanism Of Action 81

R&D Progress 81

Cellular Immunotherapy for Oncology-Drug Profile 82

Product Description 82

Mechanism Of Action 82

R&D Progress 82

Cellular Immunotherapy to Target GM-CSFR for Pancreatic Cancer-Drug Profile 83

Product Description 83

Mechanism Of Action 83

R&D Progress 83

ceritinib-Drug Profile 85

Product Description 85

Mechanism Of Action 85

R&D Progress 85

glufosfamide-Drug Profile 90

Product Description 90

Mechanism Of Action 90

R&D Progress 90

GS-5745-Drug Profile 92

Product Description 92

Mechanism Of Action 92

R&D Progress 92

GSK-2256098-Drug Profile 94

Product Description 94

Mechanism Of Action 94

R&D Progress 94

HuMab-5B1-Drug Profile 96

Product Description 96

Mechanism Of Action 96

R&D Progress 96

ibrutinib-Drug Profile 100

Product Description 100

Mechanism Of Action 100

R&D Progress 100

INCB-52793-Drug Profile 125

Product Description 125

Mechanism Of Action 125

R&D Progress 125

indoximod-Drug Profile 126

Product Description 126

Mechanism Of Action 126

R&D Progress 126

irinotecan hydrochloride-Drug Profile 131

Product Description 131

Mechanism Of Action 131

R&D Progress 131

MesoCART-Drug Profile 142

Product Description 142

Mechanism Of Action 142

R&D Progress 142

Monoclonal Antibody Conjugate to Target Mesothelin for Oncology-Drug Profile 143

Product Description 143

Mechanism Of Action 143

R&D Progress 143

napabucasin-Drug Profile 145

Product Description 145

Mechanism Of Action 145

R&D Progress 145

nimotuzumab-Drug Profile 151

Product Description 151

Mechanism Of Action 151

R&D Progress 151

palbociclib-Drug Profile 155

Product Description 155

Mechanism Of Action 155

R&D Progress 155

PBI-05204-Drug Profile 165

Product Description 165

Mechanism Of Action 165

R&D Progress 165

pelareorep-Drug Profile 167

Product Description 167

Mechanism Of Action 167

R&D Progress 167

PLX-7486-Drug Profile 181

Product Description 181

Mechanism Of Action 181

R&D Progress 181

PRI-724-Drug Profile 182

Product Description 182

Mechanism Of Action 182

R&D Progress 182

ribociclib succinate-Drug Profile 184

Product Description 184

Mechanism Of Action 184

R&D Progress 184

SGT-53-Drug Profile 188

Product Description 188

Mechanism Of Action 188

R&D Progress 188

sonidegib phosphate-Drug Profile 190

Product Description 190

Mechanism Of Action 190

R&D Progress 190

TG-01-Drug Profile 195

Product Description 195

Mechanism Of Action 195

R&D Progress 195

tosedostat-Drug Profile 198

Product Description 198

Mechanism Of Action 198

R&D Progress 198

ubidecarenone-Drug Profile 203

Product Description 203

Mechanism Of Action 203

R&D Progress 203

ulixertinib-Drug Profile 206

Product Description 206

Mechanism Of Action 206

R&D Progress 206

Vaccine for Oncology-Drug Profile 207

Product Description 207

Mechanism Of Action 207

R&D Progress 207

Metastatic Adenocarcinoma of The Pancreas-Dormant Projects 208

Metastatic Adenocarcinoma of The Pancreas-Discontinued Products 209

Metastatic Adenocarcinoma of The Pancreas-Product Development Milestones 210

Featured News & Press Releases 210

Aug 04, 2016: Merrimack Provides Update on ONIVYDE 210

Jul 21, 2016: Baxalta receives CHMP positive opinion on Onivyde for the treatment of metastatic adenocarcinoma of the pancreas 210

Jun 21, 2016: Merrimack to Present New Analyses of Phase 3 NAPOLI-1 Data at the ESMO 18th World Congress on Gastrointestinal Cancer 211

May 18, 2016: AbbVie To Present Data on IMBRUVICA (ibrutinib) at ASCO 2016 211

Apr 14, 2016: Targovax reports immune response with reduced number of TG01 vaccinations 212

Jan 25, 2016: Boston Biomedical's Investigational Cancer Stem Cell Pathway Inhibitor, Napabucasin (BBI608), Featured at the ASCO 2016 Gastrointestinal Cancers Symposium 212

Jan 07, 2016: Baxalta Announces Priority Review Status Granted by Health Canada for irinotecan liposome injection (nal-IRI) for New Drug Submission 214

Jun 25, 2015: MM-398 Receiving the Priority Review Designation by US FDA for New Drug Application and the Acceptance of Market Authorization Application by EMA in Post-Gemcitabine Metastatic Pancreatic Cancer 215

Appendix 216

Methodology 216

Coverage 216

Secondary Research 216

Primary Research 216

Expert Panel Validation 216

Contact Us 216

Disclaimer 217

List of Figures

Number of Products under Development for Metastatic Adenocarcinoma of The Pancreas, H2 2016 11

Number of Products under Development for Metastatic Adenocarcinoma of The Pancreas-Comparative Analysis, H2 2016 12

Number of Products under Development by Companies, H2 2016 13

Comparative Analysis by Late Stage Development, H2 2016 16

Comparative Analysis by Clinical Stage Development, H2 2016 17

Assessment by Monotherapy Products, H2 2016 44

Number of Products by Top 10 Targets, H2 2016 46

Number of Products by Stage and Top 10 Targets, H2 2016 46

Number of Products by Top 10 Mechanism of Actions, H2 2016 49

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 49

Number of Products by Routes of Administration, H2 2016 52

Number of Products by Stage and Routes of Administration, H2 2016 52

Number of Products by Molecule Types, H2 2016 54

Number of Products by Stage and Molecule Types, H2 2016 54

List of Tables

Number of Products under Development for Metastatic Adenocarcinoma of The Pancreas, H2 2016 11

Number of Products under Development for Metastatic Adenocarcinoma of The Pancreas-Comparative Analysis, H2 2016 12

Number of Products under Development by Companies, H2 2016 13

Number of Products under Development by Companies, H2 2016 (Contd..1) 14

Number of Products under Investigation by Universities/Institutes, H2 2016 15

Comparative Analysis by Late Stage Development, H2 2016 16

Comparative Analysis by Clinical Stage Development, H2 2016 17

Comparative Analysis by Early Stage Development, H2 2016 18

Products under Development by Companies, H2 2016 19

Products under Development by Companies, H2 2016 (Contd..1) 20

Products under Investigation by Universities/Institutes, H2 2016 21

Metastatic Adenocarcinoma of The Pancreas-Pipeline by AbbVie Inc, H2 2016 22

Metastatic Adenocarcinoma of The Pancreas-Pipeline by Aduro BioTech, Inc., H2 2016 23

Metastatic Adenocarcinoma of The Pancreas-Pipeline by Array BioPharma Inc., H2 2016 24

Metastatic Adenocarcinoma of The Pancreas-Pipeline by Axcentua Pharmaceuticals AB, H2 2016 25

Metastatic Adenocarcinoma of The Pancreas-Pipeline by Berg LLC, H2 2016 26

Metastatic Adenocarcinoma of The Pancreas-Pipeline by Boehringer Ingelheim GmbH, H2 2016 27

Metastatic Adenocarcinoma of The Pancreas-Pipeline by Boston Biomedical, Inc., H2 2016 28

Metastatic Adenocarcinoma of The Pancreas-Pipeline by CTI BioPharma Corp., H2 2016 29

Metastatic Adenocarcinoma of The Pancreas-Pipeline by CytRx Corporation, H2 2016 30

Metastatic Adenocarcinoma of The Pancreas-Pipeline by Daiichi Sankyo Company, Limited, H2 2016 31

Metastatic Adenocarcinoma of The Pancreas-Pipeline by Eleison Pharmaceuticals LLC, H2 2016 32

Metastatic Adenocarcinoma of The Pancreas-Pipeline by Gilead Sciences, Inc., H2 2016 33

Metastatic Adenocarcinoma of The Pancreas-Pipeline by GlaxoSmithKline Plc, H2 2016 34

Metastatic Adenocarcinoma of The Pancreas-Pipeline by Incyte Corporation, H2 2016 35

Metastatic Adenocarcinoma of The Pancreas-Pipeline by MabVax Therapeutics Holdings, Inc., H2 2016 36

Metastatic Adenocarcinoma of The Pancreas-Pipeline by Merrimack Pharmaceuticals, Inc., H2 2016 37

Metastatic Adenocarcinoma of The Pancreas-Pipeline by NewLink Genetics Corporation, H2 2016 38

Metastatic Adenocarcinoma of The Pancreas-Pipeline by Novartis AG, H2 2016 39

Metastatic Adenocarcinoma of The Pancreas-Pipeline by Oncolytics Biotech Inc., H2 2016 40

Metastatic Adenocarcinoma of The Pancreas-Pipeline by Pfizer Inc., H2 2016 41

Metastatic Adenocarcinoma of The Pancreas-Pipeline by Phoenix Biotechnology, Inc., H2 2016 42

Metastatic Adenocarcinoma of The Pancreas-Pipeline by Targovax ASA, H2 2016 43

Assessment by Monotherapy Products, H2 2016 44

Assessment by Combination Products, H2 2016 45

Number of Products by Stage and Target, H2 2016 47

Number of Products by Stage and Mechanism of Action, H2 2016 50

Number of Products by Stage and Route of Administration, H2 2016 53

Number of Products by Stage and Molecule Type, H2 2016 55

Metastatic Adenocarcinoma of The Pancreas-Dormant Projects, H2 2016 208

Metastatic Adenocarcinoma of The Pancreas-Discontinued Products, H2 2016 209

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AbbVie Inc

Aduro BioTech, Inc.

Array BioPharma Inc.

Axcentua Pharmaceuticals AB

Berg LLC

Boehringer Ingelheim GmbH

Boston Biomedical, Inc.

CTI BioPharma Corp.

CytRx Corporation

Daiichi Sankyo Company, Limited

Eleison Pharmaceuticals LLC

Gilead Sciences, Inc.

GlaxoSmithKline Plc

Incyte Corporation

MabVax Therapeutics Holdings, Inc.

Merrimack Pharmaceuticals, Inc.

NewLink Genetics Corporation

Novartis AG

Oncolytics Biotech Inc.

Pfizer Inc.

Phoenix Biotechnology, Inc.

Targovax ASA

Metastatic Adenocarcinoma of The Pancreas Therapeutic Products under Development, Key Players in Metastatic Adenocarcinoma of The Pancreas Therapeutics, Metastatic Adenocarcinoma of The Pancreas Pipeline Overview, Metastatic Adenocarcinoma of The Pancreas Pipeline, Metastatic Adenocarcinoma of The Pancreas Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com